התחל במצב לא מקוון עם האפליקציה Player FM !
פודקאסטים ששווה להאזין
בחסות


1 Interrogation Nation - Full Police Interrogations, Serial Killer Docs and True Crime Investigations
MDT perspectives on why and how to implement continuous glucose monitoring in T2D
Manage episode 479575832 series 3389426
Listen to key experts from a multidisciplinary team review and discuss why and how to implement continuous glucose monitoring in T2D.
The multidisciplinary team
- Endocrinologist: Prof Tina Vilsbøll
- Primary Care Physician: Dr Gihane Zarifa
- Nurse specialist: Ms. Lori Berard
- Patient advocate: Mr. Ostap Soroka
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/
498 פרקים
Manage episode 479575832 series 3389426
Listen to key experts from a multidisciplinary team review and discuss why and how to implement continuous glucose monitoring in T2D.
The multidisciplinary team
- Endocrinologist: Prof Tina Vilsbøll
- Primary Care Physician: Dr Gihane Zarifa
- Nurse specialist: Ms. Lori Berard
- Patient advocate: Mr. Ostap Soroka
This touchPODCAST is for HCPs only.
This activity is funded by an independent medical education grant from Novo Nordisk. This activity is provided by touchIME. touchIME is an EBAC® accredited provider.
For further information visit our website: https://touchendocrinologyime.org/mdt-empowering-t2d-management-the-evolution-of-basal-insulin-therapy/
498 פרקים
كل الحلقات
×
1 Navigating the treatment of RRMM with BCMA-directed therapies: Updates from COMy, ASCO and EHA 2025 1:09:32

1 Advancing care for patients with infantile haemangiomas: Timing is key 17:14

1 Incorporating ADCs into the treatment of mBC: Practical considerations for the community oncologist 35:34

1 Multidisciplinary management of TNBC Integrating immunotherapies for early and metastatic disease 36:07

1 Applying immunotherapy in clinical practice for patients with early-stage NSCLC 16:33

1 Applying immunotherapy in clinical practice for patients with early-stage NSCLC 16:33

1 Towards personalized care for people living with HIV: Supporting open dialogue and informed treatment choices 34:02

1 RET-positive NSCLC: Translating insights into targeted approaches 14:36

1 RET-positive NSCLC: Translating insights into targeted approaches 14:36

1 Advances in dry eye disease: From diagnosis to new treatment targets 37:43

1 Recent advances in the care of patients with geographic atrophy: Bringing new and emerging therapies into focus 35:33

1 The potential of BTKi therapies in delaying MS progression 13:32

1 Reducing burden of disease in gMG: Exploring the role of FcRn inhibitors 30:27

1 MDT perspectives on why and how to implement continuous glucose monitoring in T2D 13:26

1 MDT perspectives on evolving options for insulin therapy 10:05

1 MDT perspectives on understanding clinical inertia in T2D 12:14

1 Navigating the clinical impact of TROP2-targeting in NSCLC 55:41

1 Navigating the clinical impact of TROP2-targeting in NSCLC 55:41

1 Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchNEUROLOGY 33:43

1 Integrating treatment advances for alpha-mannosidosis into effective MDT care - touchENDOCRINOLOGY 33:45

1 The evolving standard of care for advanced/recurrent endometrial cancer: A practice-focused discussion of immunotherapy 38:58

1 Tailoring treatment in myelofibrosis: Addressing anaemia and thrombocytopenia 35:35

1 Video 3: MDT perspectives on identifying and managing key ADC treatment toxicities in patients with metastatic breast cancer 11:54

1 Video 2: MDT perspectives on communicating ADC treatment toxicities to patients with metastatic breast cancer 13:03

1 Video 1: MDT perspectives on the safety profiles of current and emerging ADCs in metastatic breast cancer 11:59

1 Precision in practice: Adopting emerging therapies for retinal diseases to reduce burden of disease 19:12

1 Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

1 Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:27

1 Expanding horizons for patients with Pompe disease: Using data to guide clinical practice 1:06:26

1 Expanding horizons for patients with Pompe disease Using data to guide clinical practice 1:06:27

1 MDT perspectives on the importance of patient engagement in PARPi use - Video 3 13:21

1 MDT perspectives on understanding precision medicine to guide PARPi use in mCRPC - Video 2 13:45

1 MDT perspectives on unlocking the data on PARPi to support shared decision-making in mCRPC - Video 1 13:44

1 The next frontier in managing obesity and T2D: The role of novel combinations for touchENDOCRINOLOGY 32:02

1 The next frontier in managing obesity and T2D: The role of novel combinations for touchCARDIO 32:01

1 From clinical trials to clinical practice: Applying CDK4/6 inhibitors in HR+/HER2– early breast cancer 36:50

1 Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

1 Cervical cancer prevention and beyond: Optimizing HPV vaccine uptake in all eligible individuals 36:26

1 Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

1 Looking to the future in the treatment of steroid-refractory chronic GvHD 16:31

1 Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

1 Updates in BCMA-directed therapies in multiple myeloma from ASH 2024 55:57

1 RAS mutations and personalized cancer care: Targeting the future 31:02

1 What’s new in primary ITP? Key updates from ASH 2024 40:35

1 What’s new in primary ITP? Key updates from ASH 2024 40:35

1 Focused insights: Data implications of ADCs in NSCLC treatment 21:54

1 Focused insights: Data implications of ADCs in NSCLC treatment 21:54

1 Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchONCOLOGY 1:20:58

1 Collaboration in chronic ITP: Improving quality of life and patient outcomes - touchSYMPOSIUM for touchHAEMATOLOGY 1:20:58

1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchONCOLOGY 37:37

1 Management of neurofibromatosis: Optimizing treatment and care from childhood to adult life - touchNEUROLOGY 37:38

1 Advancing the treatment of muscle-invasive bladder cancer: Updates on immunotherapy in the perioperative setting 38:15

1 Navigating treatment choices in high-risk early-stage melanoma - touchDERMATOLOGY 34:20

1 Navigating treatment choices in high-risk early-stage melanoma - touchONCOLOGY 34:19

1 Advances in IOL technology and power calculations: Updates and innovations from 2024 13:58

1 Supporting healing in epidermolysis bullosa: Innovations and new directions for care 18:55

1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31

1 Primary biliary cholangitis: Appraising the changing therapeutic landscape 35:31

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 4 13:46

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 3 16:05

1 touchMDT for touchRESPIRATORY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14

1 touchMDT for touchRESPIRATORY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57

1 touchMDT for touchRESPIRATORY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53

1 touchMDT for touchONCOLOGY - What impact could immune checkpoint inhibitors (ICIs) have on the management of patients with limited-stage small cell lung cancer (LS-SCLC)? 15:14

1 touchMDT for touchONCOLOGY - What are the key data for immune checkpoint inhibitors (ICIs) in the treatment of limited-stage small cell lung cancer (LS-SCLC)? 13:57

1 touchMDT for touchONCOLOGY - What is the rationale for using immune checkpoint inhibitors (ICIs) in limited-stage small cell lung cancer (LS-SCLC)? 14:53

1 Vaccination strategies for pneumococcal disease 33:06

1 Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 52:36

1 Optimizing treatment of CML in the first-line setting and beyond: Insights from EHA 2024 and ESH-iCMLf 2024 52:36

1 Pharmacological management of agitation in Alzheimer's dementia 34:28

1 touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchRESPIRATORY 35:33

1 touchIN CONVERSATION - Pulmonary arterial hypertension: A practical roadmap from diagnosis to treatment - touchCARDIO 35:33

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 14:12

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 15:59

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 1 14:12

1 touchMDT: Precision targeting of MET in NSCLC: A multidisciplinary approach - Discussion 2 15:59

1 Targets in early NSCLC: A focus on EGFR-mutant treatment options 16:22

1 Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 57:31

1 Targeting BCMA in multiple myeloma: Insights from COMy and EHA 2024 57:31

1 Innovations in glaucoma care: Targeting pathophysiology to expand treatment options 33:45

1 Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents 40:07

1 Experts in dermatology discuss the latest in treating moderate-to-severe atopic dermatitis in children and adolescents 40:07

1 Updates in recurrent/metastatic nasopharyngeal carcinoma: The evolving role of immune checkpoint inhibitors 18:41

1 touchMDT – Pruritus in PBC and me: The patient experience – Discussion 1 - touchIMMUNOLOGY 12:49

1 touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchIMMUNOLOGY 14:47

1 touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchIMMUNOLOGY 15:05

1 touchMDT – A comprehensive approach to symptom care in PBC – Discussion 3 - touchDERMATOLOGY 15:04

1 touchMDT – Symptom assessment and monitoring in clinical practice – Discussion 2 - touchDERMATOLOGY 14:46
ברוכים הבאים אל Player FM!
Player FM סורק את האינטרנט עבור פודקאסטים באיכות גבוהה בשבילכם כדי שתהנו מהם כרגע. זה יישום הפודקאסט הטוב ביותר והוא עובד על אנדרואיד, iPhone ואינטרנט. הירשמו לסנכרון מנויים במכשירים שונים.